ASCO® 2024 Highlights: Presenter Vignette – Paolo Ascierto
Paolo Ascierto
PA, MD
Istituto Nazionale Tumori Fondazione "G. Pascale"
Abstract# 9504
Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048.
Studies/trials discussed:
- Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048.
